Telehealth clinics occupy an awkward SEO position. You are a legitimate healthcare business competing for patients who search rather than click ads, but your category sits inside the strictest scrutiny in consumer search: health information where being wrong hurts people. Meanwhile the advertising platforms treat you as sensitive, referral pathways that work for brick-and-mortar practices do not translate, and the SEO vendors who cold-email you have mostly worked on ecommerce.

Links matter here for the ordinary reason, which is that authority accrues to sites other credible sites reference. But the way you acquire them has an unusual property in this category: the content that carries your links is advertising for a healthcare service, and it is being read by more parties than your customers.

The Enforcement Backdrop You Should Know

Two things happened recently that should shape how any telehealth operator thinks about marketing copy, and neither is obscure.

First, the FTC brought and settled an action against a telemedicine company over its weight-loss program marketing. The agency’s announcement of the final order against telehealth provider NextMed describes the alleged conduct: selling programs with undisclosed costs and membership commitments, making unsubstantiated claims about client weight loss, using fake testimonials, and unfairly distorting consumer reviews. The order requires competent and reliable evidence for claims about average or typical results, bars misrepresenting the cost of telehealth services, and prohibits manipulated or incentivized reviews.

Second, and more pointed for anyone in the compounded GLP-1 space: in March 2026 the agency announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products offered on their websites. Not their manufacturing. Their websites. That batch followed an earlier and larger wave, and the pattern regulators describe is consistent: marketing that suggests a compounded product is equivalent to an approved one, when compounded drugs have not been reviewed by FDA for safety, effectiveness, or quality at all.

Put those together and the conclusion is uncomfortable but clear. In telehealth, the marketing asset and the regulatory exhibit are the same document. That is a different situation than a dentist buying links, and it means the standard playbook is not merely suboptimal here; it is a liability generator.

What This Rules Out

Several common link building tactics are simply unavailable to you, and it is better to know that upfront than to discover it through a vendor’s invoice.

Results-driven content. The angle that converts best in weight management and hormone therapy is patient outcomes, and outcome claims require substantiation held before publication. A guest post structured around dramatic typical results is a claim, not a story.

Testimonial-led placements. Patient stories are the most linkable content you could theoretically produce and the most dangerous. Fabricated or incentivized testimonials are squarely prohibited, and real ones carry both privacy considerations and the representativeness problem.

Comparison content against approved drugs. If you work with compounded products, content positioning them against FDA-approved equivalents is exactly the territory the warning letters addressed.

Anything that obscures cost. The NextMed order specifically reached misrepresenting what is included in the price of telehealth services. Content that markets a monthly figure without the full picture is not just bad practice now; it is named conduct.

What Actually Works Instead

The constraint turns out to point somewhere productive. What remains available to you is clinical credibility, and that happens to be what earns durable links anyway.

The state-by-state angle deserves emphasis because it is underused and defensible. The federal government’s own guidance on licensing across state lines lays out why: a provider generally needs a full license from the board in the state where the patient is located, some states carve out exceptions for neighboring states or infrequent care, some offer a telehealth registration pathway for out-of-state licensees, and multi-state compacts streamline the paperwork while preserving each state’s oversight. That is a genuinely confusing landscape, patients do not understand what is available to them where they live, and a clinic that explains it accurately has produced something worth referencing that contains no efficacy claim whatsoever. That is the shape of content that earns links in a category where you cannot make promises.

The Regulator You Forgot

Operators tend to think about federal agencies because federal agencies make news. The regulator most likely to actually affect your practice is your state board, and state boards read advertising too.

Medical boards in most states have rules on physician advertising that predate telehealth entirely and apply to it anyway: prohibitions on false or deceptive statements, restrictions on claims of superiority, requirements around testimonials, sometimes specific rules on before-and-after imagery. Pharmacy boards have their own. These bodies license you, and the enforcement mechanism is your ability to practice, which is a sharper instrument than a civil penalty.

The complication for a multi-state telehealth clinic is that you are subject to the rules of every state where your patients are located, and those rules are not uniform. A guest post that is fine in one state’s advertising framework may violate another’s. Nobody writes content state by state, and nobody expects you to. But it means your floor should be the strictest reading available, not the most permissive, and it means a vendor who says “this is fine, we do it for everyone” is telling you they have not considered the question.

It also means the licensure content angle has a second benefit beyond being defensible. A clinic that visibly understands the state framework signals to boards, referrers, and patients that it takes the regulatory structure seriously. That is a credibility asset, and credibility is what you are actually buying when you build links.

Vetting a Provider

The vendor conversation should sound different than it would for an ecommerce brand. The questions that matter:

Who writes, and do they know this category? A writer who does not know that typical-results claims need substantiation will produce copy that reads well and creates exposure. Ask them to describe the line. Vague answers are answers.

Do I approve before publication? Non-negotiable. Post-hoc reporting is not review, and in this category an unreviewed sentence on a third-party site is a published claim you did not vet.

Will you show host organic traffic? Domain scores can be manufactured by the same tactics being sold. Real readers cannot. A provider who offers only scores has told you what the sites are.

Who else in health do you serve? If your clinic’s content sits on the same hosts as gray-market sellers, your brand is in a neighborhood regulators are already reading. Ask directly.

What happens when I strike a claim? Resistance reveals whose interests the model serves. A provider whose conversion depends on edge-of-the-line phrasing will fight you every article.

Beyond that, know how to verify the work yourself rather than trusting a report; the walkthrough on auditing which links actually point at your site covers the mechanics, and it keeps the relationship honest.

The Page You Point At Matters More Than the Link

A detail that gets lost in link conversations: the placement is only half the transaction. The other half is the page receiving the link, and in telehealth that page is doing double duty as a marketing asset and a regulatory exhibit.

If you build links to a service page whose copy contains the exact claims regulators have been citing, you have not just bought a link. You have bought traffic and attention for the specific document you would least like scrutinized, and you have added a durable third-party signal pointing at it. Building authority to a weak page is the ordinary version of this mistake. Building authority to a legally exposed page is the telehealth version, and it is worse.

So the sequence matters. Audit the destination pages before you commission placements. Get the pricing disclosure right, get the compounded-product language reviewed if that applies to you, remove the typical-results framing, make sure clinician credentials are real and visible. Then point links at pages that can survive being read closely. This is slower than the alternative and it is the whole difference between authority that compounds and exposure that compounds.

Where a Private Network Fits

The access problem is genuine. Mainstream health publishers are cautious about DTC telehealth, the open guest-post market will not touch the category seriously, and cold outreach at a rejection rate this high does not pencil out. A private network built for restricted and regulated industries addresses access and compliance together. ALT Placements runs one for regulated verticals, with aged niche-relevant domains, daily distribution rather than spikes, hand-written hosting content, and reporting that gives you dates, anchors, and snippets.

The tradeoff is real and worth naming: the network is private, so publisher URLs are undisclosed. You are trading a specific transparency for access. For a telehealth operator, the thing to establish before committing is the copy control, since the way content gets produced and approved is the part that determines whether you are buying authority or exposure. If a provider cannot articulate why a typical-results claim is different from a process explainer, they are not equipped for this category regardless of what their domain list looks like.

Frequently Asked Questions

Is buying links risky for a telehealth clinic?

There are two risks and they are not equal. The search risk is the ordinary one: links acquired to move rankings can be devalued. The regulatory risk is larger and specific, because published content about your services is advertising, and both the FTC and FDA have recently demonstrated they read telehealth marketing copy closely. The second risk is why review authority matters more than link volume.

Can we publish patient success stories?

Carefully, and less usefully than you would hope. Testimonials must reflect real experience, cannot be incentivized toward a sentiment, and claims about typical results require substantiation. Add patient privacy considerations and the practical answer for most clinics is that success-story content is high-effort, high-risk, and lower-yield than clinician-authored educational content.

What about compounded medications in our content?

This is the sharpest edge in the category right now. FDA warning letters to telehealth companies have targeted website claims about compounded GLP-1 products, particularly marketing that presents them as equivalent to approved drugs. If compounded products are part of your model, your marketing copy needs legal review, not a content vendor’s judgment.

How long does telehealth SEO take to work?

Longer than most categories, because search systems apply heightened scrutiny to health content and authority accrues slowly when it accrues honestly. Expect a couple of months before movement and closer to half a year for a meaningful picture, assuming the pages being linked deserve to rank. Anyone promising faster in this vertical is describing something other than what happens.

Do we need clinicians involved in content?

Practically, yes. Health content that ranks and holds up tends to carry real clinical authorship, and it is also the best defense against a writer wandering into a claim. Clinician review is slower and it is the difference between content that builds authority and content that creates a record.

The Bottom Line

Link building for a telehealth clinic works, but only if you accept that your marketing copy lives in two worlds at once. The tactics that convert fastest in this vertical are the ones regulators have recently named: outcome claims without substantiation, testimonials that are not what they appear, pricing that omits the real cost, compounded products positioned against approved ones. What is left is narrower and more durable, which is clinical expertise, factual access information, and process transparency published under real names on sites with real readers. Vet providers on whether they understand that distinction. In this category, the vendor who is easiest to work with is usually the one writing the sentence you will have to explain.